Short Interest in Bruker Corporation (NASDAQ:BRKR) Declines By 16.1%

Bruker Corporation (NASDAQ:BRKR) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 11,497,888 shares, a drop of 16.1% from the November 30th total of 13,704,909 shares. Currently, 10.4% of the shares of the company are sold short. Based on an average daily trading volume, of 2,221,732 shares, the days-to-cover ratio is currently 5.2 days. Based on an average daily trading volume, of 2,221,732 shares, the days-to-cover ratio is currently 5.2 days. Currently, 10.4% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Cowen restated a “hold” rating on shares of Bruker in a report on Tuesday, November 4th. Rothschild & Co Redburn started coverage on shares of Bruker in a research report on Thursday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. TD Cowen increased their target price on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday, November 4th. Finally, Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $51.38.

Bruker Price Performance

Shares of Bruker stock opened at $47.51 on Wednesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85. The firm’s 50-day simple moving average is $44.18 and its 200-day simple moving average is $39.06. Bruker has a twelve month low of $28.53 and a twelve month high of $64.64. The firm has a market cap of $7.22 billion, a P/E ratio of -296.94, a price-to-earnings-growth ratio of 7.13 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.12. The firm had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, research analysts expect that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s payout ratio is currently -125.00%.

Insider Transactions at Bruker

In other Bruker news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director directly owned 35,212 shares of the company’s stock, valued at $1,373,268. The trade was a 15.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 27.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Trexquant Investment LP acquired a new stake in shares of Bruker during the 1st quarter worth about $4,122,000. Royal Bank of Canada boosted its position in Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after buying an additional 9,501 shares in the last quarter. Focus Partners Advisor Solutions LLC bought a new stake in Bruker during the first quarter worth about $332,000. VeriStar Capital Management LP acquired a new stake in shares of Bruker during the first quarter worth approximately $3,473,000. Finally, Dark Forest Capital Management LP bought a new position in shares of Bruker in the first quarter valued at approximately $4,296,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.